These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

632 related articles for article (PubMed ID: 21790210)

  • 21. [Infections and fingolimod].
    Cervera C
    Rev Neurol; 2012 Aug; 55(4):227-37. PubMed ID: 22829086
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
    Cohen JA; Barkhof F; Comi G; Izquierdo G; Khatri B; Montalban X; Pelletier J; Eckert B; Häring DA; Francis G
    J Neurol; 2013 Aug; 260(8):2023-32. PubMed ID: 23632946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Fingolimod treatment in multiple sclerosis].
    Tanaka M
    Nihon Rinsho; 2014 Nov; 72(11):2010-4. PubMed ID: 25518386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.
    Al-Hashel J; Ahmed SF; Behbehani R; Alroughani R
    CNS Drugs; 2014 Sep; 28(9):817-24. PubMed ID: 25011422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
    Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
    Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J; So TY
    Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vagomimetic effects of fingolimod: physiology and clinical implications.
    Vanoli E; Pentimalli F; Botto G
    CNS Neurosci Ther; 2014 Jun; 20(6):496-502. PubMed ID: 24836740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Central effects of fingolimod.
    Cruz VT; Fonseca J
    Rev Neurol; 2014 Aug; 59(3):121-8. PubMed ID: 25030072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Roskell NS; Zimovetz EA; Rycroft CE; Eckert BJ; Tyas DA
    Curr Med Res Opin; 2012 May; 28(5):767-80. PubMed ID: 22462530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
    Ward MD; Jones DE; Goldman MD
    Expert Opin Drug Saf; 2014 Jul; 13(7):989-98. PubMed ID: 24935480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.
    Chinea Martinez AR; Correale J; Coyle PK; Meng X; Tenenbaum N
    Adv Ther; 2014 Oct; 31(10):1072-81. PubMed ID: 25245812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fingolimod therapy for multiple sclerosis.
    Willis MA; Cohen JA
    Semin Neurol; 2013 Feb; 33(1):37-44. PubMed ID: 23709211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fingolimod for the treatment of relapsing multiple sclerosis.
    Singer BA
    Expert Rev Neurother; 2013 Jun; 13(6):589-602. PubMed ID: 23738997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS
    J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
    Lee CW; Choi JW; Chun J
    Arch Pharm Res; 2010 Oct; 33(10):1567-74. PubMed ID: 21052934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
    Massberg S; von Andrian UH
    N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
    [No Abstract]   [Full Text] [Related]  

  • 38. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
    J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fingolimod-associated macular edema: incidence, detection, and management.
    Jain N; Bhatti MT
    Neurology; 2012 Feb; 78(9):672-80. PubMed ID: 22371414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
    Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
    Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.